According to a recent LinkedIn post from Acclaro Medical, the company is emphasizing its UltraClear-branded Laser-Coring technology for skin resurfacing. The post describes how the 2910 nm fiber-enabled system creates microchannels that remove columns of excess skin with minimal bleeding and faster healing compared with traditional mechanical coring.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests Acclaro Medical is positioning UltraClear as a differentiated, efficiency-focused alternative in the aesthetic laser segment. For investors, this focus on a proprietary 2910 nm fiber laser platform could support premium pricing, procedure adoption, and recurring demand from aesthetic practices, potentially strengthening the company’s competitive profile in energy-based dermatology devices.